Clinical trials: Double-Filtration Plasmapheresis
Microplastic and Nanoplastic Particle Burden in Peripheral Blood, Double-Filtration Plasmapheresis
Evaluating DFPP for Microplastic and PFAS Reduction
This prospective, non-interventional, within-subject paired biomarker study will evaluate whether circulating microplastic and nanoplastic-associated particle concentrations and PFAS concentrations in peripheral blood change…
- Trial name
- DFPP-MNP (NCT07658443)
- Testing
- Double-Filtration Plasmapheresis With the IN300 Apheresis Device
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Proxima Health, Inc.
Kidney Transplantation, Antibody Mediated Rejection
Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange
In France around 90,000 cases of end-stage chronic kidney disease patients treated either by dialysis (60%) or renal transplantation (just over 40%).
- Trial name
- DFPP (NCT03436134)
- Testing
- Sessions of conventional apheresis, Sessions of news apheresis with double filtration
- Where
- France
- Volunteers
- 16 people
- Sponsor
- University Hospital, Grenoble
Sub-healthy, Hyperlipidemia
The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood.
- Conditions
- Sub-healthy, Hyperlipidemia, Toxic Metal Ions Accumulation
- Trial name
- NCT06224296
- Testing
- DFPP
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Hepatitis C
Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load
Hepatitis C virus (HCV) infection, a leading cause of cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation, affects approximately 170 million individuals worldwide.
- Trial name
- NCT00977054
- Testing
- DFPP + Peg-IFN + RBV, Peg-IFN + RBV
- Where
- 6 sites in Taiwan
- Volunteers
- 59 people
- Sponsor
- National Taiwan University Hospital
Kidney Failure
Evaluation of the Efficacy and Tolerance of Plasmapheresis by Double Cascade Filtration in a University Centre
A study is being carried out to evaluate the biological, technical and clinical/biological efficacy of this technique, the practice of which is standardized in the department, in order to evaluate our practices and to improve…
- Trial name
- DFPPSURV (NCT04261205)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
DFPP and Platelet Function
Double Filtration Plasmapheresis (DFPP) and Lipid Metabolism
Little clinic trials showed that Double Filtration Plasmapheresis (DFPP) could improve lipid metabolism, however, whether DFPP can improve platelet function and recover Endothelial function is unknown.
- Trial name
- NCT03491956
- Testing
- DFPP
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pudong Hospital
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
CIDP, a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without antibodies but with modified cell profiles have been described.
- Trial name
- LYMPHOARESIS (NCT04742374)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Lipoprotein(a), Lipoprotein-apheresis
Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )
Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (>200 nmol/L) who…
- Conditions
- Lipoprotein(a), Lipoprotein-apheresis, Double-filtration Plasmapheresis, Hemodialysis Complication
- Trial name
- LiPo-A (NCT07390604)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Kidney Transplantation
Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates
Kidney transplantation is the treatment of choice for end-stage renal disease. ABO incompatible (ABOi) living donor kidney transplantation is one of the best ways to expand the donors' pool.
- Trial name
- DADI (NCT03477656)
- Testing
- Large volume specific immunoadsorption, Double Filtration Plasmapheresis
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
The Clinical Efficacy of DFPP in Patients With AAGN
The clinical efficacy of double filtration plasmapheresis(DFPP) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).
- Trial name
- NCT02294344
- Testing
- DFPP&CTX, CTX
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Zhi-Hong Liu, M.D.
Pneumonia, Ventilator-Associated, Coronavirus Infection
Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients
The 2019 outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID 19), which originated in Wuhan, China, has become a major concern all over the world.
- Trial name
- NCT04346589
- Testing
- Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients
- Where
- 5 sites in Italy
- Volunteers
- 9 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Pneumonia, Viral, Corona Virus Infection
Convalescent Antibodies Infusion in COVID 19 Patients
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world.
- Trial name
- NCT04418531
- Testing
- Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients
- Sponsor
- Piero Luigi Ruggenenti
Multiple Myeloma
Double Filtration Plasmapheresis Combined With Chemotherapy
Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment of abnormalities of M protein or renal function due to the multiple myeloma.
- Trial name
- NCT04836871
- Testing
- DFPP combined with chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuling Zhou
Hyperfibrinogenemia, Hemostatic Disorder
Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Few reliable data are available on these changes and most studies are limited to coagulation factor assays before and…
- Trial name
- APHERCOAG (NCT06571552)
- Testing
- Single Plasma Exchange followed by Double Filtration Plasmapheresis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Plasmapheresis
A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study
Global demand for therapeutic plasmapheresis is rising to treat various immunological, rheological, and lipoprotein-related disorders.
- Trial name
- CFPP (NCT07515404)
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Kidney Transplant Rejection, Plasmapheresis
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
At present, the number of end-stage kidney disease patients is increasing. Kidney transplant surgery is one of the treatments that give patients a better survival rate than hemodialysis or abdominal dialysis.
- Conditions
- Kidney Transplant Rejection, Plasmapheresis, Kidney Replacement
- Trial name
- NCT03965559
- Testing
- plasmapheresis
- Volunteers
- 30 people
- Sponsor
- Chiang Mai University